Loading...
Please wait, while we are loading the content...
Similar Documents
Intravenous trypsin in experimental myocardial infarction.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Agress, C. M. Jacobs, H. I. Binder, Mascha Clark, William G. Kaplan, Lee Lederer, M. A. Glassne, H. F. |
| Copyright Year | 1954 |
| Abstract | The possibility of using intravenous proteolytic agents in the treatment of acute myocardial infarc-tion lias been studied. The coronary arteries of closed-chest dogs were embolized with small repetitive doses of fibrin clots until definite electrocardiographic evidence of myocardial injury which persisted for at least two hours was observed. The treated animals were given up to six intravenous infusions of 250,000 Armour units of trypsin in 250 ml. saline over a period of eight days, and the survivors were sacrificed on the ninth day. The control animals received no trypsin. These studies showed that trypsin caused dissolution of the host thrombus which formed around the fibrin clots, without damage to the infarcted tissue; that the coronary vessels were recanalized; that the extent of infarction was decreased; and that the electrocardiographic changes were improved and the mortal it v was reduced. I NTEREST; in the use of intravenous proteolytic enzymes in the treatment of thrombotic diseases has gained new impetus with the advent of a crystalline preparation of trypsin for parenteral use. Innerfield was the first to use intravenous trypsin for the treatment of human thrombotic diseases. 1 However , to our knowledge, no animal experiments have been reported on the use of intravascular proteolytic agents for the treatment of arterial thrombi, particularly coronary arterial thrombi. This paper is a report on results obtained from dogs treated with trypsin after experimental coronary artery embolization. The following questions have been investigated: (a) Can intravenous administration of a pro-teolytic enzyme (trypsin*) cause recanaliza-tion of the coronary vessels of the dog after Chicago, Illinois. This drug is now packaged under the name of "Kitzar." embolization with fibrin particles; (b) is this type of treatment contraindicated in the presence of acutely infarcted myocardium because of the possibility of myocardial rupture; and (c) what blood pressure and electrocardio-graphic changes result from the administration of repeated large doses of tiypsin under conditions of severe myocardial injury? METHODS Preparation of Fibrin Clots. 2000 X.I.H. units of bovine thrombint were added to 250 cc. of reconstituted human plasma. The resulting clot was filtered and washed repeatedly with saline until reduced to a yellow-white fibrin network. This fibrin clot was then lyophilized, broken up into particles, and passed through a no. 40 U.S. Standard sieve. Only those particles of the fibrin clot were used which passed through this sieve, but not through a no. 50 sieve. These particles were then sterilized … |
| Starting Page | 397 |
| Ending Page | 404 |
| Page Count | 8 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://circres.ahajournals.org/content/circresaha/2/5/397.full.pdf?download=true |
| Alternate Webpage(s) | http://circres.ahajournals.org/content/circresaha/2/5/397.full.pdf |
| PubMed reference number | 13190618v1 |
| Volume Number | 2 |
| Issue Number | 5 |
| Journal | Circulation research |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Angiotensin-Converting Enzyme Inhibitors Arterial system Arteries Blood Clot Blood Vessel Canis familiaris Cardiomyopathies Cattle Clomiphene Clotrimazole Congenital Abnormality Congenital Heart Defects Coronary Artery Disease Coronary Vessels Coronary artery Electrocardiography Gain Hematological Disease Intravenous infusion procedures Myocardial Infarction Myocardial Ischemia Myocardial rupture Myocardium Obstruction Survivors Thrombosis Yellow Fever Vaccine |
| Content Type | Text |
| Resource Type | Article |
